Endeavor® Vs. Taxus®: Medtronic, Inc.’s Drug-Eluting Coronary Stent Linked to Fewer Heart Attacks at Two Years Post Implant

WASHINGTON--(BUSINESS WIRE)--Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), is associated with statistically fewer heart attacks than Boston Scientific’s Taxus® DES.